Cabaletta Bio, Inc. filed a current report on September 14, 2026 disclosing the final exercise results for Common Stock Warrants issued in its June 2025 underwritten public offering, with aggregate gross proceeds from all exercises totaling approximately $128.2 million.

Key Highlights

  • Total warrants issued: 53,090,190 Common Stock Warrants were issued in connection with the June 2025 underwritten public offering.
  • Exercise price: Each warrant carried an exercise price of $2.50 per whole share of common stock.
  • Expiration date: The warrants expired on September 12, 2026.
  • Early exercises: 5,275,100 warrants were exercised from issuance through June 30, 2026, generating approximately $13.2 million in aggregate gross proceeds.
  • Late-period exercises: 46,011,900 warrants were exercised from July 1, 2026 through the expiration date, generating approximately $115.0 million in aggregate gross proceeds.
  • Total proceeds: Aggregate gross proceeds from all warrant exercises totaled approximately $128.2 million.

Cabaletta Bio Reports Full Warrant Exercise Cycle from June 2025 Offering

According to the filing, Cabaletta Bio, Inc. (NASDAQ:CABA), a Delaware-incorporated biopharmaceutical company headquartered in Philadelphia, Pennsylvania, issued 53,090,190 Common Stock Warrants in conjunction with a June 2025 underwritten public offering. Each warrant entitled the holder to purchase one whole share of the company's common stock at an exercise price of $2.50 per share. The warrants carried an expiration date of September 12, 2026.

The company disclosed that warrant exercises occurred across two distinct periods. From the time of issuance through June 30, 2026, holders exercised 5,275,100 of the Common Stock Warrants, producing aggregate gross proceeds of approximately $13.2 million. In the subsequent period from July 1, 2026 through the September 12, 2026 expiration date, 46,011,900 Common Stock Warrants were exercised, resulting in aggregate gross proceeds of approximately $115.0 million. Combined, the two periods account for 51,287,000 total warrants exercised, with the filing reporting total aggregate gross proceeds of approximately $128.2 million from issuance through the expiration date.

The filing was made under Item 8.01 (Other Events) and was signed by Steven Nichtberger, Chief Executive Officer and President, in his capacity as Principal Executive Officer. No forward-looking statements or additional business updates were included in the current report beyond the warrant exercise disclosure described above.

What Was Disclosed

Cabaletta Bio reported the completed exercise activity for 53,090,190 Common Stock Warrants from its June 2025 public offering, disclosing that exercises across two time periods generated aggregate gross proceeds of approximately $128.2 million prior to the September 12, 2026 expiration date.